Azlocillin sodium salt - 10mM in DMSO, high purity , CAS No.37091-65-9(DMSO)

Item Number

A408124

• Specifications & Purity: 10mM in DMSO
• Biochemical and Physiological Mechanisms: Azlocillin is an acylampicillin with a broad spectrum against bacteria.
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

Information

Azlocillin is an acylampicillin with a broad spectrum against bacteria.
In vitro

Azlocillin (12.5 μg/mL) inhibits over 75% of the isolates of Pseudomonas aeruginosa. Azlocillin (12.5 μg/mL) is also active against indole-negative and -positive Proteus spp., inhibiting 98 and 71%, respectively. Azlocillin is more active than mezlocillin, ticarcillin, and carbenicillin and as active as BLP-1654 against isolates of P. aeruginosa. The acyl side chains of Azlocillin have an ureido-(urea) structurehence the name "ureidopenicillins" or, more specifically, "acylureidopenicillins." In vitro studies against P. aeruginosa demonstrates that piperacillin has activity that is twice that of azlocillin, 4 times that of mezlocillin and ticarcillin, and about 8 times that of carbenicillin. Azlocillin produces elongated bacterial forms with delayed or no lysis in morphologic studies. Azlocillin has MICs of 12.5 μg/mL on Pseudomonas aeruginosa. Azlocillin (3.125 μg/mL) results in a reduction in the rate of growth but no bactericidal phase on Pseudomonas aeruginosa. Azlocillin decreases an initial lag phase with increasing drug concentration. At the lower concentration of tobramycin (0.5 μg/ml), the combinations with both the high and the low concentrations of Azlocillin are more effective than the individual components on Pseudomonas aeruginosa. Isolates with derepression of AmpC enzyme are one to two doubling dilutions more resistant to azlocillin than are those in which increased efflux or impermeability is inferred. Those with secondary β-lactamases are mostly (12/14 cases) susceptible to ceftazidime at 4 mg/L, but are amongst the most resistant to Azlocillin (MIC ≥128 mg/L in 10/14 cases).

In vivo

Azlocillin/netilmicin treatment results in infections inhibition rate of 42% (28/67) in the empirical therapy of febrile neutropenic patients. Azlocillin/netilmicin treatment results in 15% adverse events in the empirical therapy of febrile neutropenic patients.
Cell Data

cell lines：MDA361, U87MG, HCT116, LNCap and HT29 cells

Concentrations：

Incubation Time：

Powder Purity:≥99%